Clinical trial
Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in…
NCT00026104 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00026104 |
|---|---|
| Title | Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer |
| Official title | A Randomized Phase II Trial of Weekly Gemcitabine, Paclitaxel and External Irradiation (50.4 GY) Followed by the Farnesyl Transferase Inhibitor R115777 (NSC #702818) for Locally Advanced Pancreatic Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Collaborators | NRG Oncology |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of the Pancreas, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer |
| Intervention type | Drug, Radiation |
| Interventions | gemcitabine hydrochloride, paclitaxel, tipifarnib, radiation therapy |
| Enrollment | 154 |
| Start date | Nov 1, 2001 |
| Primary completion | Aug 1, 2006 |
| First posted | Jan 27, 2003 |
| Last update posted | Oct 30, 2020 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: